Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes
Imperial College London
160 participants
Feb 7, 2023
INTERVENTIONAL
Conditions
Summary
Glucose monitoring after Acute Myocardial infarct in people with diabetes is a Dexcom funded study that is investigating whether the use of continuous glucose monitors (Dexcom ONE model) in people with type 2 diabetes facilitates time in glycaemic range in the 6 months after an acute myocardial infarction. As an exploratory outcome it will investigate whether time in glycaemic range is associated with changes in mortality and major adverse cardiac events in the 6 months after acute myocardial infarct.
Eligibility
Inclusion Criteria11
- From the Hammersmith Hospital In-patient Cardiology Services:
- Adults aged \>18 years
- Known or newly diagnosed type 2 diabetes
- Taking one or more oral hypoglycaemic agent, GLP1 receptor analogue and/or insulin
- Admitted to Hammersmith Hospital cardiology inpatient services with ACS
- Raised blood troponin level on admission
- From Imperial College Healthcare Trust Diabetes and Cardiology Clinics:
- Adults aged \>18 years
- Known type 2 diabetes
- Previous acute coronary syndrome within the last 10 years but \> 6 months ago
- Taking one or more oral hypoglycaemic agent and /or GLP1 receptor analogue, and/or insulin
Exclusion Criteria21
- From the Hammersmith Hospital In-patient Cardiology Services:
- HbA1c \<48mmol/mol
- People who have previously had bariatric surgery
- People taking hydroxyurea
- People who undergo haemodialysis or peritoneal dialysis
- Unable to participate due to other factors, as assessed by the Chief Investigators
- Pregnancy as determined by clinical team
- Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year
- From Imperial College Healthcare Trust Diabetes and Cardiology Clinics:
- HbA1c \<48mmol/mol
- People who have previously had bariatric surgery
- People taking hydroxyurea
- People who undergo haemodialysis or peritoneal dialysis
- Unable to participate due to other factors, as assessed by the Chief Investigators
- Pregnancy as determined by clinical team
- Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year
- Previous acute coronary syndrome more than 10 years ago or within the last 6 months
- Withdrawal criteria
- The subject has a serious event related to the study
- Investigated initiated discontinuation of study due to participation or equipment concerns
- Withdrawal of consent
Interventions
The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05431296